These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 22146578)

  • 1. Platelet function profile post-clopidogrel therapy in patients with type 2 diabetes undergoing coronary stent implantation.
    Saad AA; Ismail EA; Darwish YW; Nasr HA; Hassan AR; Bedeer I; Alfons MA
    Clin Appl Thromb Hemost; 2012 Jun; 18(3):249-57. PubMed ID: 22146578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
    Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
    Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
    J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting.
    Antonino MJ; Mahla E; Bliden KP; Tantry US; Gurbel PA
    Am J Cardiol; 2009 Jun; 103(11):1546-50. PubMed ID: 19463513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Hernández-Antolín R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Macaya C
    J Invasive Cardiol; 2004 Jun; 16(6):325-9. PubMed ID: 15156004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
    Cuisset T; Quilici J; Grosdidier C; Fourcade L; Gaborit B; Pankert M; Molines L; Morange PE; Bonnet JL; Alessi MC
    Am J Cardiol; 2011 Nov; 108(10):1411-6. PubMed ID: 21872198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
    J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment.
    Bernlochner I; Steinhubl S; Braun S; Morath T; Jaitner J; Stegherr J; Mehilli J; von Beckerath N; Schömig A; Kastrati A; Sibbing D
    Thromb Haemost; 2010 Dec; 104(6):1193-200. PubMed ID: 20838744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Mielot C; Bali L; Lambert M; Alessi MC; Bonnet JL
    Thromb Haemost; 2007 Feb; 97(2):282-7. PubMed ID: 17264958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention.
    Mangiacapra F; Patti G; Peace A; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Muller O; Barbato E; Di Sciascio G
    Am J Cardiol; 2010 Sep; 106(5):619-23. PubMed ID: 20723634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
    Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
    Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment.
    Angiolillo DJ; Costa MA; Shoemaker SB; Desai B; Bernardo E; Suzuki Y; Charlton RK; Zenni MM; Guzman LA; Bass TA
    Am J Cardiol; 2008 Feb; 101(4):440-5. PubMed ID: 18312754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
    Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
    Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
    Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Barrera-Ramirez C; Sabaté M; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
    Thromb Res; 2005; 115(1-2):101-8. PubMed ID: 15567460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients.
    Harmsze AM; Van Werkum JW; Moral F; Ten Berg JN; Hackeng CM; Klungel OH; De Boer A; Deneer VH
    Platelets; 2011; 22(2):98-102. PubMed ID: 21142408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation.
    Siller-Matula JM; Haberl K; Prillinger K; Panzer S; Lang I; Jilma B
    Thromb Res; 2009 Apr; 123(6):874-80. PubMed ID: 19135705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Kuliczkowski W; Greif M; Gąsior M; Kaczmarski J; Pres D; Poloński L
    Kardiol Pol; 2011; 69(6):531-7. PubMed ID: 21678284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
    Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
    Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
    Moerenhout CM; Claeys MJ; Haine S; Miljoen H; Bosmans JM; Vertessen F; Kluppels K; Van der Planken M; Vrints CJ
    Am Heart J; 2010 Mar; 159(3):434-8. PubMed ID: 20211306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.